What does EURO PHARMA do?

EURO PHARMA is a road haulage company in Grâce-Hollogne. Private Limited, started on 5 April 2022, 1 establishment.

What is the address of EURO PHARMA?

The registered office of EURO PHARMA is located at Rue Sélys Longchamps(Jean de) 27, 4460 Grâce-Hollogne.

Is EURO PHARMA still active?

Yes. According to the CBE (17 September 2026) EURO PHARMA is active, legal situation “Normale toestand”, started on 5 April 2022.

Is EURO PHARMA registered on Peppol?

Yes, EURO PHARMA is registered on the Peppol network with ID 0208:0784494230.

What is the enterprise number of EURO PHARMA?

The enterprise number of EURO PHARMA is BE0784494230.

When was EURO PHARMA founded?

EURO PHARMA was founded on 5 April 2022.

Who are the directors of EURO PHARMA?

According to the 2025 annual accounts, the directors of EURO PHARMA are: Marc SMETS.

Is EURO PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 April 2022; 3 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did EURO PHARMA make in 2025?

EURO PHARMA recorded a loss after taxes of € 36,405 in financial year 2025.

What is the revenue of EURO PHARMA?

As a small company, EURO PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 17,760.

EURO PHARMA (Private Limited) - Grâce-Hollogne

Dossier EURO PHARMA, printed on 17 September 2026 from databakkes.be/en/0784494230/euro-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 3 of the last 3 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 17 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

EURO PHARMA from Grâce-Hollogne, company number BE0784494230, closed financial year 2025 with a result of € -36,405 after tax. For that financial year EURO PHARMA recorded a gross margin of € 17,760 and equity of € -435,082. Compared with financial year 2024, the result moved from € -324,206 to € -36,405. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.

What it is worth Caution

€ -435,082

▼ € 36,405 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -36,405

▲ 89 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 547

▼ 48% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -440,082.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost estimate Staff cost at a one-person company Staff Only people on the payroll count here.€ 35 Likely the director’s social contribution or pension premium.The director’s pay Already netted into the gross margin, not shown separately in the accounts. Typical for one-person companies € 45,000 gross per year minimum for the reduced tax rate≈ € 2,100 net per month after contributions, tax and usually some benefits in kind, roughly Assumption based on the chart of accounts, not a figure from the source.

€ 35

▼ 91% vs 2024

No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.

Vehicles and equipment

€ 69,067

▲ 130% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 186,663

▼ 24% vs 2024

€ 61,306 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 143,059

▲ 19% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -69,552 Gross margin 2023: € -69,552 First fiscal year in the series	€ -235,902 Gross margin 2024: € -235,902 ▼ € 166,351 vs 2023 (€ -69,552) Unfavourable step	€ 17,760 Gross margin 2025: € 17,760 ▲ € 253,662 vs 2024 (€ -235,902) Favourable step	▲ € 253,662
Profit after taxes	€ -79,470 Profit after taxes 2023: € -79,470 First fiscal year in the series	€ -324,206 Profit after taxes 2024: € -324,206 ▼ € 244,736 vs 2023 (€ -79,470) Unfavourable step	€ -36,405 Profit after taxes 2025: € -36,405 ▲ € 287,801 vs 2024 (€ -324,206) Favourable step	▲ € 287,801
Equity	€ -74,470 Equity 2023: € -74,470 First fiscal year in the series	€ -398,676 Equity 2024: € -398,676 ▼ € 324,206 vs 2023 (€ -74,470) Unfavourable step	€ -435,082 Equity 2025: € -435,082 ▼ € 36,405 vs 2024 (€ -398,676) Unfavourable step	▼ € 36,405
Total debts	€ 429,708 Total debts 2023: € 429,708 First fiscal year in the series	€ 590,160 Total debts 2024: € 590,160 ▲ 37% vs 2023 (€ 429,708) Unfavourable step	€ 654,723 Total debts 2025: € 654,723 ▲ 11% vs 2024 (€ 590,160) Unfavourable step	▲ 11%
Cash	€ 42,821 Cash 2023: € 42,821 First fiscal year in the series	€ 1,050 Cash 2024: € 1,050 ▼ 98% vs 2023 (€ 42,821) Unfavourable step	€ 547 Cash 2025: € 547 ▼ 48% vs 2024 (€ 1,050) Unfavourable step	▼ 48%
Retained profit	€ -79,470 Retained profit 2023: € -79,470 First fiscal year in the series	€ -403,676 Retained profit 2024: € -403,676 ▼ € 324,206 vs 2023 (€ -79,470) Unfavourable step	€ -440,082 Retained profit 2025: € -440,082 ▼ € 36,405 vs 2024 (€ -403,676) Unfavourable step	▼ € 36,405
Bank debt	€ 301,435 Bank debt 2023: € 301,435 First fiscal year in the series	€ 245,318 Bank debt 2024: € 245,318 ▼ 19% vs 2023 (€ 301,435) Favourable step	€ 186,663 Bank debt 2025: € 186,663 ▼ 24% vs 2024 (€ 245,318) Favourable step	▼ 24%
Balance sheet total	€ 355,238 Balance sheet total 2023: € 355,238 First fiscal year in the series	€ 191,483 Balance sheet total 2024: € 191,483 ▼ 46% vs 2023 (€ 355,238) Unchanged	€ 219,641 Balance sheet total 2025: € 219,641 ▲ 15% vs 2024 (€ 191,483) Unchanged	▲ 15%

Key figures of EURO PHARMA, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to EURO PHARMA?

What happened at EURO PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 30, 2026 New annual accounts for financial year 2025: loss of € 36,405. Source: NBB ↗
Apr 5, 2022 New establishment in Grâce-Hollogne. KBO
Apr 5, 2022 Start of the company according to the CBE. KBO
2022 Marc SMETS became a director. NBB

In short

From € 79,470 loss in 2023 to € 36,405 loss in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at EURO PHARMA? We notify you, reason included.

Follow EURO PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Marc SMETS

EURO PHARMA

Behind EURO PHARMA is Marc SMETS.

See the full network in the app

Directors

According to the 2025 annual accounts

Marc SMETS

Director

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Sélys Longchamps(Jean de) 27

4460 Grâce-Hollogne

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0784.494.230

VAT number

BE 0784.494.230

Registered office

Rue Sélys Longchamps(Jean de) 27, 4460 Grâce-Hollogne

Names & denominations

EURO PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

5 April 2022

Peppol

Active · Active since 24 Sept 2025

Activities · NACE

Goederenvervoer over de weg

Opslag

Logistieke diensten

Overige vervoerondersteunende activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗

EURO PHARMA

Warning lights

Financials

What happened to EURO PHARMA?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions